Closed Solicitation · DEPARTMENT OF VETERANS AFFAIRS

    6505--NOTICE OF INTENT - SOLE SOURCE FOR PLUVICTO

    DEPARTMENT OF VETERANS AFFAIRS
    Sol. 36C25225F0191Special NoticeMILWAUKEE, WI
    Closed
    STATUS
    Closed
    closed Aug 26, 2025
    POSTED
    Aug 19, 2025
    Publication date
    NAICS CODE
    325412
    Primary industry classification
    PSC CODE
    6505
    Product & service classification

    AI Summary

    The Department of Veterans Affairs intends to award a sole source contract to Novartis Pharmaceuticals for the purchase of Pluvicto, a specialized radiopharmaceutical for treating metastatic castration-resistant prostate cancer. This notice is not a request for proposals, and interested parties must provide evidence of their capability by the specified deadline.

    Contract details

    Solicitation No.
    36C25225F0191
    Notice Type
    Special Notice
    Posted Date
    August 19, 2025
    Response Deadline
    August 26, 2025
    NAICS Code
    325412AI guide
    PSC / Class Code
    6505
    Primary Contact
    Parris S Weidenbach
    State
    WI
    ZIP Code
    53214
    AI Product/Service
    product

    Description

    The Department of Veterans Affairs, VHA Regional Procurement Office Central, Great Lakes Acquisition Center, Network Contracting Office 12, located at 115 S. 84th Street, Suite 101, Milwaukee, WI 53214-1476 intends to award a sole source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation 59 Route 10, East Hanover, NJ 07936, for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing. The Edward J. Hines, Jr. VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141-3030, has a requirement for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) is a highly specialized radiopharmaceutical. Pluvicto is a radiologic therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pluvicto is an FDA approved drug. Pluvicto manufactured and is a trademark of Novartis Pharmaceuticals Corporation. This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. No solicitation documents are available at this time. Interested parties may give written notice to Parris.Weidenbach@va.gov by 5:00pm e.s.t. on 08/26/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to Parris.Weidenbach@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.

    Key dates

    1. August 19, 2025Posted Date
    2. August 26, 2025Proposals / Responses Due

    AI search tags

    Frequently asked questions

    6505--NOTICE OF INTENT - SOLE SOURCE FOR PLUVICTO is a federal acquisition solicitation issued by DEPARTMENT OF VETERANS AFFAIRS. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.